Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 10, 2024

BUY
$2.78 - $21.53 $5 - $43
2 Added 1.59%
128 $0
Q4 2023

Feb 09, 2024

BUY
$13.92 - $21.0 $890 - $1,344
64 Added 103.23%
126 $2,000
Q3 2023

Nov 13, 2023

BUY
$7.58 - $16.08 $204 - $434
27 Added 77.14%
62 $0
Q2 2023

Aug 15, 2023

SELL
$5.06 - $9.91 $9,770 - $19,136
-1,931 Reduced 98.22%
35 $0
Q1 2023

May 12, 2023

BUY
$7.94 - $15.6 $15,610 - $30,669
1,966 New
1,966 $19,000
Q3 2022

Nov 14, 2022

SELL
$7.61 - $22.29 $350 - $1,025
-46 Reduced 63.01%
27 $0
Q2 2022

Aug 12, 2022

BUY
$7.7 - $18.82 $562 - $1,373
73 New
73 $1,000

Others Institutions Holding ANTX

About AN2 Therapeutics, Inc.


  • Ticker ANTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 19,402,700
  • Market Cap $20.8M
  • Description
  • AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menl...
More about ANTX
Track This Portfolio

Track Wells Fargo & Company Portfolio

Follow Wells Fargo & Company and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

News

Stay updated on Wells Fargo & Company with notifications on news.